Amgen

KANJINTI - Cost

Last Updated: April 1st, 2024

HCPCS:

Q5117

HCPCS Code Descriptor:

Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg

Medicare Payment Limit:

The KANJINTI Medicare Payment Limit is $17.681

Average Sale Price:

KANJINTI ASP cost available once logged in. Kanjinti is a biosimilar drug making the ASP calculation more complex. Kanjinti's ASP is based on the average sale price of its biosimilar reference drug.

Medicare Co-Insurance Percentage:

The KANJINTI Medicare Co-insurance percentage is 20%. KANJINTI's Medicare Co-insurance amount is $3.54 per HCPCS unit.

APC Code:

The Kanjinti APC Code is: 9330

APC Payment Limit:

The APC Payment Limit for KANJINTI is available. Login to view.

Kanjinti Cost Information:

Kanjinti is a trastuzumab biosimilar with a HCPCS Code, Q5117, that became effective on October 1st, 2019. Since its effective date, Kanjinti took a small change to its list price in September 2021. Similar to other trastuzumab biosimilars, Kanjinti’s ASP steadily declined in the presence of biosimilar discounting competition. As of January 2024, Kanjinti’s ASP over 90% since October of 2019.

ACCESS PRICING AND MORE BY REGISTERING

Kanjinti’s wholesale acquisition cost (WAC) information was last updated on:
May 1, 2023
Kanjinti’s average wholesale price (AWP) information was last updated on:
May 1, 2023